Skip to content
Navigate to homepage - Cerba Research
Resource Library

White Paper – The Importance Of NGS Panel Customization For Your Assays: Good Practices And Key Takeaways

As cancer remains a major global health concern, precision medicine brings hope for patients for improved treatments and outcomes. Explore the pivotal role of Next-Generation Sequencing (NGS) panel customization in driving advancements in oncology research. From biomarker identification to actionable mutation detection, molecular profiling forms the bedrock of precision medicine. Learn how NGS panel customization is revolutionizing this landscape, enabling simultaneous analysis of diverse genetic aberrations for a comprehensive cancer understanding.

Traditional methods like Sanger sequencing and PCR are limited to single-gene analysis, making them impractical for new target discovery. NGS’s ability to analyse millions of segments in parallel accelerates research, while customized panels provide deeper, cost-effective insights into genomic abnormalities.

Discover insights on:

  1. NGS Advantages: Delve into the superiority of NGS over traditional methods, facilitating efficient and sensitive analysis.
  2. Clinical Implementation: See how NGS is enhancing patient care through improved molecular profiling in clinical trials and practice.
  3. Personalized Therapies: Understand how tailored panels enable personalized and precise targeted therapies by identifying actionable mutations.
  4. Latest Techniques: Explore the application of NGS to formalin-fixed paraffin-embedded (FFPE) samples and the innovative use of circulating tumor DNA (ctDNA).

Elevate your understanding of precision oncology’s potential. Download our white paper to harness the benefits of NGS panel customization. Empower your oncology research and clinical practice with insights that will help transform your research and advance health for patients.

 

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help transform research and advance health.

Resource Library

White Paper – Precision Medicine For Non-Small Cell Lung Cancer (NSCLC) – Emerging Trends In Molecular Analysis

Of all types of cancer, lung cancer caused more deaths worldwide than any other type of cancer. It also causes more deaths than breast and colorectal cancers combined. Patients with the most common lung cancer, non-small cell lung cancer (NSCLC), have higher survival rates than patients with small-cell lung cancer (SCLC), but the outcomes for both remain bleak. According to the National Cancer Institute, the five-year survival rate for NSCLC between 2004 and 2010 was 20.7% compared to only 6.3% for SCLC.2

NSCLC patients also have more promising and more precise, treatment options today compared to even 10 years ago. Advances in biomarker and precision medicine have led to the development of immunotherapies and targeted novel treatments that have the potential to improve patient outcomes. In the United States, the FDA has approved dozens of biomarker-driven therapies for NSCLC, including ALK, EGFR, and ROS1 inhibitors. Meanwhile, more than 1,200 treatments are in development.

Discover the latest trends in precision medicine for NSCLC in this white paper

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts to see how we can help advance your clinical trial

Contact Us
Resource Library

Brochure – Cerba Research Genomics Experience In Oncology

Since 1992, Cerba Research/Healthcare has pioneered the art of human genetic testing, Cerba Healthcare builds the start of the art in human genetic testing by being the first laboratory in Europe to introduce Genetic testing.

Thanks to this experience, we are able to collaborate with the life science community to provide the most suitable genomic service and enhance the power of your genetic material.

Cerba Research can work with you to select the most suitable platform and assay to reach your project expectations.

Discover all our capabilities in our latest Genomics Brochure

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform research and advance health in the field of genomics.

Contact Us
Resource Library

White Paper – Nonnegotiable Central Laboratory Capabilities For I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated clinical laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts & discover how we can help you transform research and advance health

Contact Us
Resource Library

Webinar – Turning Precision Medicine Into Action In Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Resource Library

Webinar – Challenges Of Covid-19 Testing: Which Test To Use?

Are you using the right Covid-19 test? In the race to contain the COVID-19 pandemic, efficient detection of SARS-CoV-2 was and still remains the cornerstone. On January 23, the first in-house RT-PCR assay was published, quickly followed by the development of multiple commercial kits.

During the webinar, our Cerba biologists will walk participants through the overview of our available testing, discuss the reliability of tests, the current limits in Covid-19 testing, and which sample is the most efficient in each case.

Lastly, Cerba Research’s partner Fulgent will discuss NGS testing and how much we know about the analysis of the virus and its mutations.

Resource Library

Flyer – CerbACT Asia – Center Of Excellence In Immuno-Oncology

CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Presence And Capabilities – Running Clinical Trials In Australia Infographic

With Cerba’s network spanning five continents, team up with our experienced scientists to generate early insights and direct the course of your complex trial.

Our locations consist of cutting-edge laboratories that provide a full portfolio of specialty laboratory testing, anchored by seven centers in the Americas, Europe, Africa, and Asia-Pacific regions. With consistent, high-quality data and a road map to the patients you need, we empower you to develop personalized medicines and diagnostic solutions that will change lives worldwide.

Discover our Australia capabilities

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us
Resource Library

Presentation – Next Generation Biomarker Discovery

Strong & Sustainable Partnership

Learn how Cerba Research and Fulgent are enhancing genomic data in clinical trials for better patient outcomes across all phases through their NGS services. In this presentation, you’ll learn how we’re accelerating precision medicine with next generation biomarker discovery through our partnership and specific expertise in oncology, rare disease, CNS, metabolic, and infectious diseases.

Resource Library

Brochure – Cerba Research’s Multi-Omics Approaches In Hematological Malignancies

Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.

Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.

At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us